María
Díez Campelo
University of Texas MD Anderson Cancer Center
Houston, Estados UnidosPublications en collaboration avec des chercheurs de University of Texas MD Anderson Cancer Center (9)
2024
-
Hematopoietic stem cells with granulo-monocytic differentiation state overcome venetoclax sensitivity in patients with myelodysplastic syndromes
Nature Communications, Vol. 15, Núm. 1
2023
-
Consensus proposal for revised International Working Group 2023 response criteria for higher-risk myelodysplastic syndromes
Blood
-
Improved benefit of continuing luspatercept therapy: sub-analysis of patients with lower-risk MDS in the MEDALIST study
Annals of Hematology, Vol. 102, Núm. 2, pp. 311-321
2022
2021
-
Daratumumab in transfusion-dependent patients with low or intermediate-1 risk myelodysplastic syndromes
American Journal of Hematology
-
Phase III, Randomized, Placebo-Controlled Trial of CC-486 (Oral Azacitidine) in Patients With Lower-Risk Myelodysplastic Syndromes
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 39, Núm. 13, pp. 1426-1436
-
Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification—an approach to classification of patients with t-MDS
Leukemia, Vol. 35, Núm. 3, pp. 835-849
2020
-
Luspatercept in patients with lower-risk myelodysplastic syndromes
New England Journal of Medicine, Vol. 382, Núm. 2, pp. 140-151